Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 14/20 | 0.49 |
| ▸ | GAA | P10253 | 14/20 | 0.49 |
| ▸ | SI | P14410 | 14/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 14/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CBFB | Q13951 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7850069 | 0.84 | MGAM (0.50) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL11782292 | 0.79 | MGAM (0.46) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL6972586 | 0.79 | HPSE (0.46) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL21855798 | 0.79 | ADORA1 (0.56) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL16342366 | 0.79 | CBFB (0.45) | GAACBFBKDM4ENPC1RAB9A | |
| SCHEMBL6973496 | 0.78 | RIPK1 (0.41) | GAAALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL3413861 | 0.78 | HPSE (0.55) | MGAMGAASIMGAM2HPSE | |
| Hydrochloric Acid SCHEMBL11786682 | 0.78 | HPSE (0.45) | MGAMGAASIMGAM2ESR1 | |
| Hydrochloric Acid SCHEMBL11789101 | 0.78 | HPSE (0.45) | MGAMGAASIMGAM2ESR1 | |
| Hydrochloric Acid SCHEMBL11576683 | 0.77 | HPSE (0.53) | MGAMGAASIMGAM2HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212169-B2 | Benzimidazole derivative and use thereof | HYOGO COLLEGE OF MEDICINE (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212169-B2 | Benzimidazole derivative and use thereof | HYOGO COLLEGE OF MEDICINE (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212169-B2 | Benzimidazole derivative and use thereof | HYOGO COLLEGE OF MEDICINE (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150011600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | KAGOSHIMA UNIVERSITY (JP) | 2015-01-08 | — | — | US | disclosed |
| US-20150011600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | KAGOSHIMA UNIVERSITY (JP) | 2015-01-08 | — | — | US | disclosed |
| US-20150011600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | KAGOSHIMA UNIVERSITY (JP) | 2015-01-08 | — | — | US | disclosed |
| EP-1286987-A1 | HETEROCYCLIC HYDRAZONES FOR USE AS ANTI-CANCER AGENTS | Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung (AT) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001094340-A1 | HETEROCYCLIC HYDRAZONES FOR USE AS ANTI-CANCER AGENTS | INNOVATIONSAGENTUR GESELLSCHAFT M.B.H. (AT) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | HDAC1, HDAC11, HDAC6 | MGAM 3834/4885GAA 473/4885SI 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.